Abstract: The present invention relates to compounds of Formula (I) wherein Ar1, A, R1 and R2 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

Abstract: The present invention relates to compounds of Formula (I) wherein Ar1, R1 and R2 are as described in the description, and A is 4,5-dihydroisoxazole-3,5-diyl, imidazolidin-4-one-1,3-diyl, oxazol-2-one-3,5-diyl and oxazolidine-2-one-3,5-diyl, 1,2,3-triazole-1,4-diyl, isoxazole-3,5-diyl, imidazole-1, 4-diyl, and isothiazole-3,5-diyl; and their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

Abstract: The present invention relates to compounds of Formula (I) wherein Ar1, A, B, and R1 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

Abstract: The present invention relates to compounds of Formula (I) wherein Ar1, Ar2, L, n, and R1 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

Abstract: The present invention relates to compounds of Formula (I) wherein Ar1, Ar2, L, n, and R1 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

Abstract: The present invention relates to compounds of Formula (I) wherein X, Ar1, Ar2, L, n, m, and R1 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

Abstract: The present invention relates to Galectin-3 inhibitors of Formula (I) and pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds, and their medical uses.

Abstract: The present invention relates to compounds of Formula (I) wherein Ar1, Ar2, L, n, and R1 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

Abstract: The present invention relates to compounds of Formula (I) wherein Ar1, A, B, and R1 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

Abstract: The present invention relates to compounds of Formula (I) wherein Ar1, Ar2, L, n, and R1 are as described in the description, their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

Abstract: The present invention relates to compounds of Formula (I) wherein Ar1, R1 and R2 are as described in the description, and A is 4,5-dihydroisoxazole-3,5-diyl, imidazolidin-4-one-1,3-diyl, oxazol-2-one-3,5-diyl and oxazolidine-2-one-3,5-diyl, 1,2,3-triazole-1,4-diyl, isoxazole-3,5-diyl, imidazole-1, 4-diyl, and isothiazole-3,5-diyl; and their preparation, to pharmaceutically acceptable salts thereof, and to their use as pharmaceuticals, to pharmaceutical compositions containing one or more compounds of Formula (I), and especially to their use as Galectin-3 inhibitors.

Abstract: The present invention improves the stability of a Web browser by identifying plug-in modules that cause failures. Data in memory at the time of a failure is analyzed and a failure signature is generated. The failure signature is compared to a database of known failure signatures so that the source of the failure may be identified. If a plug-in module to a Web browser is identified as the source of a failure, options are presented to the user who may update the plug-in module with code that does not produce a failure or disable the plug-in module altogether.

Abstract: The present invention provides a method and a computer-readable medium containing computer-executable instructions for allowing a user of an application program to manage add-ons associated with the application program. A user interface that displays the add-ons associated with the application program is provided. The user interface provides the user with the ability to disable or enable the add-ons, the ability to update certain type of add-ons. In addition, an administrator of the application program can approve or deny certain add-ons and disable a user's ability to disable or enable add-ons.

Abstract: An operating system registry contains multiple “identities.” One of these identities is designated the current identity. An application executing on a multitasking computer system uses information stored in the current identity to configure the application, for example to provide a user-specific user interface. When an application opens, it registers with an identity manager using objects known as “connection points.” To switch identities, a user supplies the name of an identity to switch to. The identity manager then uses the registered connection points to query each of the applications for permission to switch identities. If all the registered connection points grant permission to switch identities, then the identity manager switches the current identity by changing information in the registry. The identity manager then notifies all applications, via their registered connection points, that a change to the registry has been made so that the applications can take appropriate action.

Abstract: An operating system registry contains multiple “identities.” One of these identities is designated the current identity. An application executing on a multitasking computer system uses information stored in the current identity to configure the application, for example to provide a user-specific user interface. When an application opens, it registers with an identity manager using objects known as “connection points.” To switch identities, a user supplies the name of an identity to switch to. The identity manager then uses the registered connection points to query each of the applications for permission to switch identities. If all the registered connection points grant permission to switch identities, then the identity manager switches the current identity by changing information in the registry. The identity manager then notifies all applications, via their registered connection points, that a change to the registry has been made so that the applications can take appropriate action.